Biopharma Dealmaking Quarterly Statistics, Q2 2013
A look at the financing, M&A, and alliance activity April-June 2013
Q2 2013 biopharma financing increased 139% to $11 billion over Q1’s $4.6 billion, thanks mostly to two huge transactions by Valeant to fund its $8.7 billion takeover of ophthalmics player Bausch & Lomb, the company’s largest acquisition to date. Options and antibody-drug conjugates featured prominently in the alliances.
You may also be interested in...
Amgen will acquire the cancer company Onyx for $125 per share, or $10.4 billion. That's higher than the $120 per share Amgen originally offered, but less than some investors and analysts thought obtainable.
The fast-growing, Canadian specialty pharma will shed thousands of jobs as it absorbs Bausch & Lomb, as part of an endeavor to save $800 million. CEO Mike Pearson’s note to employees describes a new organizational philosophy, with restructured management and business units.
The British pharma has done the biggest takeout of a private, clinical-stage European biotech so far this year. It is focused on a Phase I RSV vaccine and a T-cell stimulating technology. As for VCs, they have nabbed roughly a 10x return on their invested capital.